Accel, Mint and Pharmascience recall some drugs over efficacy test data concerns
Health Canada says the move comes from concerns over bioequivalence test data, which is used to show that a pharma company's generic prescription drug works the same as the brand-name counterpart.
![Accel, Mint and Pharmascience recall some drugs over efficacy test data concerns](https://i.cbc.ca/1.7229350.1717867601!/fileImage/httpImage/image.jpg_gen/derivatives/16x9_620/accel-ondansetron-odt.jpg)
![A box of medical tablets is pictured.](https://i.cbc.ca/1.7229350.1717867601!/fileImage/httpImage/image.jpg_gen/derivatives/16x9_620/accel-ondansetron-odt.jpg)
Health Canada says the move comes from concerns over bioequivalence test data, which is used to show that a pharma company's generic prescription drug works the same as the brand-name counterpart.